Exhibit 10.41
ROYALTY AGREEMENT
This ROYALTY AGREEMENT ("Agreement"), dated as of June 30, 1999, is entered
into by and between Xxxxxx Healthcare Corporation, a Delaware corporation having
a place of business at 0000 Xxxx Xxxx Xxxx, Xxxxxxxxx, Xxxxxxxx 00000
("Baxter"), Nexell Therapeutics Inc., a Delaware corporation having a place of
business at Nine Xxxxxx, Xxxxxx, Xxxxxxxxxx 00000 ("Nexell Therapeutics"), and
Nexell of California, Inc., a Delaware corporation having a place of business at
Nine Parker, Xxxxxx, Xxxxxxxxxx 00000 ("Nexell California").
RECITALS
WHEREAS, Baxter and Nexell entered into a strategic alliance in the ex vivo
cell therapies business in 1997, pursuant to that certain Asset Purchase
Agreement (the "Acquisition Agreement") dated as of October 10, 1997, and those
certain related agreements referred to therein, dated as of December 17, 1997,
including, inter alia:
- the Hardware and Disposables Manufacturing Agreement (as amended, the
"Manufacturing Agreement");
- the Hardware and Disposables Supply Agreement (as amended, the "Supply
Agreement");
- the Antibody Manufacturing and Storage Agreement (as amended, the
"Antibody Agreement");
- the Services Agreement (as amended, the "Original Services Agreement");
- the Marketing, Sales and Distribution Agreement (as amended, the
"Distribution Agreement"); and
- the Non-Competition and Confidentiality Agreement (as amended, the "Non-
Compete Agreement").
WHEREAS, pursuant to the Acquisition Agreement, Baxter sold to Nexell
certain Assets relating to its Division (as that capitalized term is defined in
the Acquisition Agreement) and Business (as that capitalized term is defined in
the Acquisition Agreement).
WHEREAS, Baxter and Nexell have agreed to (a) modify the terms of their
relationship with respect to services provided by Baxter to Nexell, as set forth
in the Original Services Agreement; (b) terminate the Original Services
Agreement; (c) enter into a United States and Canada Instrument Services
Agreement and a Management Services Agreement of even date herewith, as those
capitalized terms are defined in, and pursuant to, that certain Asset Transfer
Agreement, by and among Baxter and Nexell of even date herewith (the "Asset
Transfer Agreement"); and (d) enter into
1
a European Services Agreement and additional instrument service agreements for
the rest of the world (other than the United States and Canada) to be negotiated
and agreed to by the parties on or before the ROW Asset Transfer Closing, as
those capitalized terms are defined in, and pursuant to, that certain Asset
Transfer Agreement.
WHEREAS, Baxter and Nexell have also agreed to terminate the Distribution
Agreement, pursuant to the terms of the Asset Transfer Agreement.
WHEREAS, Baxter and Nexell have agreed to enter into this Royalty Agreement
as further consideration for the Asset Transfer Agreement and in consideration
for the transfer of certain intellectual property pursuant to the Acquisition
Agreement.
NOW, THEREFORE, in consideration of the premises and the mutual covenants
contained herein, Baxter and Nexell hereby agree as follows:
1. Definitions.
1.1 Terms Defined in Preamble and Recitals: As used herein, all
capitalized terms defined in the Preamble and Recitals of this
Agreement shall bear the meanings ascribed to such terms as set
forth therein.
1.2 Other Terms: As used herein, the following capitalized terms
shall have the following meanings:
A. "Affiliate" of a party shall mean any entity (i) which
directly or indirectly through one or more intermediaries
Controls, is Controlled by or is under common Control with
the party or (ii) fifty percent (50%) or more of the voting
capital stock (or in the case of an entity which is not a
corporation, fifty percent (50%) or more of the equity
interest) of which is beneficially owned or held by a party
or any of such party's Subsidiaries. The term "Control"
means the possession, directly or indirectly, of the power
to direct or cause the direction of the management and
policies of an entity (other than a natural person), whether
through the ownership of voting capital stock, by contract
or otherwise.
B. "Distributed Products" shall bear the meaning set forth in
Schedule 1.2(B) attached hereto.
---------------
C. "Field of Distribution" means the worldwide market in
connection with the Maxsep(R) and/or Isolex(R) Products used
for the selection of cells with one or more of the XX00, X
Xxxx, X Cell or breast cancer antibodies for the treatment,
mitigation, prophylaxis or selection of/for cancer,
including the research market; and any product used for the
treatment, mitigation, prophylaxis or selection of/for
cancer based
2
upon the selection or use of CD 34+ cells,
including the research market; but excluding the genetic
manipulation of such cells.
D. "Net Sales" shall mean gross sales less returns, rebates,
and trade and cash discounts.
E. "Nexell" shall mean, individually and collectively, jointly
and severally, Nexell Therapeutics and Nexell California.
F. "Nexell Group" shall mean, individually and collectively,
jointly and severally, Nexell and any and all of Nexell's
Affiliates.
G. "Royalty Effective Date" means the first to occur of: (1)
January 1 of the first year in which annual, aggregate Net
Sales of Distributed Products in the Field of Distribution
are at least fifty million dollars ($50,000,000); or (2)
January 1, 2001.
H. "Subsidiary" means, as to any party, any corporation of
which more than fifty percent (50%) of the outstanding
capital stock having ordinary voting power to elect a
majority of the board of directors of such corporation
(irrespective of whether or not at the time stock of any
other class or classes of such corporation shall have or
might have voting power by reason of the happening of any
contingency) is at the time directly or indirectly owned by
the party, by one or more of its subsidiaries, or by the
party and one or more of its subsidiaries.
2. Term.
2.1 Term: This Agreement shall expire on December 17, 2008.
3. Royalties and Reports
3.1 Royalties: For all Distributed Products sold by the Nexell Group
on or after January 1, 2001 in the Field of Distribution, Nexell will pay
to Baxter an earned royalty of five percent (5%) of such Net Sales of
Distributed Products by the Nexell Group. If the Royalty Effective Date
occurs before January 1, 2001, Nexell will pay to Baxter an earned royalty
of: (1) five percent (5%) of worldwide Net Sales of Distributed Products by
the Nexell Group in excess of fifty million dollars ($50,000,000) per
calendar year in and for the calendar year in which the Royalty Effective
Date occurs; and (2) five percent (5%) of all worldwide Net Sales of
Distributed Products by the Nexell Group in subsequent calendar quarters.
3.2 Reports
3
(a) Nexell agrees to make written reports to Baxter quarterly, within
sixty (60) days next following the end of each calendar quarter
during the term of this Agreement, identifying in each such report
the Nexell Group's worldwide Net Sales of Distributed Products
during the preceding calendar quarter and the amount of royalty
due. Calendar quarters shall begin January 1, April 1, July 1, and
October 1 of each year. The first such report shall include all
such sales granted between June 30, 1999 and the end of the
quarter that follows the date of this Agreement.
(b) Nexell agrees to make a last written report to Baxter within sixty
(60) days after the date of termination of this Agreement for
worldwide Net Sales of Distributed Products by the Nexell Group
upon which royalties are payable hereunder but which were not
previously reported. The obligation to make reports and to pay
royalties shall terminate upon termination of this Agreement,
except that royalties accrued but not paid prior to such
termination shall be payable with the last written report of this
Section 3.2.
(c) During the term of this Agreement and for one (1) year thereafter,
Nexell agrees to keep records of all worldwide Net Sales of
Distributed Products by the Nexell Group in sufficient detail to
enable the royalties paid hereunder to be determined. Baxter may
audit the Nexell Group's books and records for the purpose of
determining compliance with the terms of this Agreement. Baxter
may use independent outside auditors (who may participate fully in
such audit). In the event that an audit is proposed with respect
to information which Nexell wishes not to disclose to Baxter
("Restricted Information"), then on the written demand of Nexell
the individuals conducting the audit with respect to the
Restricted Information will be limited to Xxxxxx'x independent
auditors. In such event, Nexell shall pay the costs of the
independent auditors conducting such audit, but only with respect
to that portion of the audit relating to the Restricted
Information. Such independent auditors shall enter into an
agreement with the relevant parties, on terms that are agreeable
to the parties, under which such independent auditors shall agree
to maintain the confidentiality of the information obtained during
the course of such audit and establishing what information such
auditors will be permitted to disclose in reporting the results of
any audit of Restricted Information. Any such audit shall be
conducted during regular business hours in a manner that does not
interfere unreasonably with the operations of Nexell. The
aggregate number of audits of Nexell's books and records conducted
under this Agreement shall not exceed one (1) financial audit in
any twelve (12) month period unless the next preceding audit
disclosed a failure to conform to the terms of this Agreement.
Subject to the foregoing limitations, any such audit shall be
conducted when requested by notice given not less than thirty (30)
days prior to the commencement of the audit. If by such audit
Baxter discovers unauthorized activities, or if the amount of
royalties due set forth in the auditor's report deviates by more
than ten percent (10%) from the amount of royalties due reported
by Nexell for the same period, Nexell shall reimburse Baxter for
the cost of the audit. Any additional amounts due to Baxter from
Nexell as the result of such an audit shall be paid by Nexell
within thirty (30) days of receipt by Nexell of a copy of the
auditor's report and a notice from Baxter of the additional
amounts due
4
3.3 Payment of Royalties: Together with each report referred to in
Section 3.2 hereof, Nexell shall pay to Baxter the applicable
royalties due as specified in this Section 3 for the worldwide Net
Sales of Distributed Products by the Nexell Group covered by the
report. All royalties or portions of royalties that remain unpaid at
the end of this 60-day period will accrue interest at a rate of 1.5%
per month or such maximum rate permitted by applicable law.
4. Xxxxxx'x Continuing Rights
4.1 Co-promotion of Distributed Products: Baxter shall be provided
the opportunity to co-promote any or all of the Distributed Products
in the Field of Distribution. Specifically, Baxter may provide
information about the Distributed Products to potential customers,
provided that any such written information (other than correspondence
-------------
that does not include information regarding the performance of the
Distributed Products) so provided by Baxter shall have been pre-
approved by an appropriate member of the Nexell Group. In the event
that such a potential customer expresses an interest in the
Distributed Products, Baxter shall refer the potential customer to an
appropriate member of the Nexell Group for further contact by the
appropriate member of the Nexell Group. No member of the Nexell Group
shall provide any Distributed Products to any such customer before
informing such customer that (a) the business and sales relationship
evidenced by such agreement is between Nexell and the customer, and
(b) that Baxter is not an agent for the Nexell Group nor a party to
the agreement between the Nexell Group and the customer. Nothing in
this Royalty Agreement shall be construed as an obligation by Baxter
to sell, market or distribute any of the Distributed Products.
4.2 Right of First Negotiation: In the event that Nexell elects to
abandon and/or discontinue substantially all efforts to develop or
market (or to have developed or marketed) the Distributed Products, or
any of them (the "Discontinued Products"), within the Field of
Distribution or any sub-field thereof, and Nexell elects to sell
---
Nexell's right to make, have made, use and sell the Discontinued
Products in the Product Field or any sub-field thereof to a third
party, Baxter shall have a right of first negotiation to obtain an
exclusive worldwide license to make, have made, use and sell in such
Product Field or sub-field, those Discontinued Products. After Nexell
notifies Baxter of Nexell's intention to sell such right, Baxter will
have sixty (60) days to respond to Nexell and to negotiate the
material terms and conditions of such a license. The terms and
conditions of such a license shall be negotiated by Nexell and Baxter,
bargaining in good faith, and documented in a written agreement,
signed by authorized representatives of both parties. If, after notice
to Baxter and expiration of sixty (60) days without completed
negotiation of the material terms of a license agreement with respect
to any Discontinued Product described in such notice, Nexell shall
have no further obligations to Baxter with respect to such specific
Discontinued Products under this Section 4.2.
5. Dispute Resolution.
5.1 Provisional Remedies: The procedures specified in this
Section 5 shall be the sole and exclusive procedures for
the resolution of disputes between the parties arising
out of or relating to this Agreement; provided, however,
-------- -------
that
5
a party, without prejudice to these procedures, may seek a
preliminary injunction or other provisional relief if, in its
sole judgment, such action is deemed necessary to avoid
irreparable damage or to preserve the status quo. During such
action, the parties will continue to participate in good faith
in the procedures specified in this Section 5.
5.2 Negotiations Between Executives: The parties will attempt in
good faith to resolve promptly any claim or controversy arising
out of or relating to the execution, interpretation or
performance of this Agreement (including the validity, scope
and enforceability of the provisions contained in this Section
5), promptly by negotiation between their designated
executives.
5.3 Arbitration: In the event that any dispute arising out of or
relating to this Agreement or its breach, termination or
validity has not been resolved after good faith negotiation
pursuant to the procedures of Section 5.2, such dispute shall,
upon written notice by either party to the other, be finally
settled by arbitration administered by the Center for Public
Resources in accordance with the provisions of its Commercial
Arbitration Rules and the United States Federal Arbitration
Act, as modified below:
A. The arbitration shall be heard by a panel of three (3)
independent and impartial arbitrators all of whom shall be
selected from a list of neutral arbitrators supplied by
the Center for Public Resources. From such list, each of
Baxter and Nexell shall select one (1) arbitrator, and the
arbitrators so selected shall select a third. The panel
shall designate one (1) among them to serve as chair.
B. The arbitration proceedings shall be conducted in Los
Angeles County or Orange County in the State of
California.
C. Any party may seek interim or provisional remedies under
the Federal Rules of Civil Procedure and the United States
Federal Arbitration Act as necessary to protect the rights
or property of the party pending the decision of the
arbitrators.
D. The parties shall allow and participate in limited
discovery for the production of documents and taking of
depositions, which shall be conducted in accordance with
the Commercial Arbitration Rules of the Center for Public
Resources. All discovery shall be completed within sixty
(60) days following the filing of the answer or other
responsive pleading. Unresolved discovery disputes shall
be brought to the attention of the chair of the
arbitration panel and may be disposed of by the chair.
E. Each party shall have up to fifty (50) hours to present
evidence and argument in a hearing before the panel of
arbitrators, provided that
6
the chair of the panel of arbitrators may establish such
longer times for presentations as the chair deems
appropriate.
F. The arbitration award shall be rendered by the arbitrators
within fifteen (15) business days after conclusion of the
hearing of the matter, shall be in writing and shall
specify the factual and legal basis for the award.
Judgment thereon may be entered in any court having
jurisdiction thereof.
G. The arbitrators are empowered to order money damages in
compensation for a party's actual damages, specific
performance or other appropriate relief to cure a breach;
provided, however, that the arbitrators will have no
-------- -------
authority to award special, punitive or exemplary damages,
or other money damages that are not measured by the
prevailing party's actual damages.
5.4 Performance During Dispute: Each party is required to continue
to perform its obligations under this Agreement pending final
resolution of any dispute arising out of or relating to this
Agreement, unless to do so would be commercially impossible or
impractical under the circumstances.
6. Choice of Law and Jurisdiction. This Agreement shall be governed by
and construed in accordance with the internal laws of the state of
Delaware, without application of conflicts of law principles, and,
subject to Section 5 above, each party hereby submits to the
jurisdiction and venue of any state or federal court in the State of
Delaware. To the extent permissible by law, each of the parties hereby
waives, releases and agrees not to assert, and agrees to cause its
Affiliates to waive, release and not assert, any rights such party or
its Affiliates may have under any foreign law or regulation that would
be inconsistent with the terms of this Agreement as governed by
Delaware law.
7. Provisions Contrary to Law/Severability. In performing this Agreement,
the parties hereto shall comply with all applicable laws. Nothing in
this Agreement shall be construed so as to require the violation of
any law, and wherever there is any conflict between any provision of
this Agreement and any applicable law, the applicable law shall
prevail. In the event any provision of this Agreement conflicts with
any applicable law or is otherwise determined by an arbitrator or
court having valid jurisdiction thereof to be unenforceable, the
affected provision of this Agreement shall be deemed to have been
modified to the extent necessary so as not to conflict with the
applicable law or to be unenforceable or, if such modification is not
possible, such provision shall be deemed to have been deleted
herefrom, without affecting, impairing or invalidating the remaining
provisions of this Agreement.
8. Entire Agreement. This Agreement, together with any exhibits or
schedules attached hereto, constitutes the entire agreement between
the parties as to the subject matter hereof, and all prior
negotiations, representations, agreements and
7
understandings are merged into, extinguished by and completely
expressed by this Agreement.
9. Waivers and Modifications. The failure of any party to insist on the
performance of any obligation hereunder shall not be deemed to be a
waiver of such obligation. Waiver of any breach of any provision
hereof shall not be deemed to be a waiver of any other breach of such
provision or any other provision. No waiver, modification, release or
amendment of any obligation under or provision of this Agreement shall
be valid or effective unless in writing signed by the party to be
bound by such waiver, modification, release or amendment.
10. No Other Licenses. Except as may otherwise be agreed to by the parties
in writing, neither party shall use the name of the other party in any
promotional materials or advertising without the prior written consent
of the other party. Neither party shall at any time assert any claim
to any goodwill, reputation or ownership of the other party's
Intellectual Property (as that capitalized term is defined in the
Manufacturing Agreement) and all uses of a party's Intellectual
Property shall inure to the benefit of that party.
12. Assignment. Nexell may assign its rights and obligations hereunder to
any Affiliate of Nexell without prior notice to or consent of Baxter,
provided that Nexell shall remain liable hereunder to Baxter
-------- ----
for all liabilities, obligations and/or duties of Nexell so assigned
to such Affilitate. Baxter may assign its rights and obligations
hereunder to any Affiliate of Baxter without prior notice to or
consent of Nexell. No assignment by Baxter or by Nexell, or by any
permitted assignee, shall be effective unless and until the assignee
shall have agreed to become bound by the provisions of the Non-Compete
Agreement to the same extent and in the same manner as Baxter (in the
case of a Baxter assignee) or Nexell (in the case of a Nexell
assignee) is bound. No party hereto may assign any of its rights or
obligations under this Agreement, unless and to the extent expressly
permitted by this Section 12. Subject to the foregoing, this Agreement
shall inure to the benefit of and be binding on the parties' permitted
successors and assigns.
13. Independent Parties. By virtue of this Agreement, neither party
constitutes the other as its agent (except as may otherwise be
expressly provided herein), partner, joint venturer, or legal
representative, and neither party has express or implied authority to
bind the other in any manner whatsoever.
14. Counterparts / Facsimile Signatures. This Agreement may be executed in
any number of counterparts with the same effect as if all parties had
signed the same document. All such counterparts shall be deemed an
original, shall be construed together, and shall constitute one and
the same instrument. Facsimile signatures of the parties shall be
binding with respect to execution of this Agreement.
15. Rules of Construction. In this Agreement, unless a clear contrary
intention appears:
8
A. The singular number includes the plural number and vice versa;
B. Reference to any party includes such party's permitted successors
and assigns;
C. Reference to any gender includes the other gender;
D. Reference to any Section, Exhibit or Schedule means such section
of this Agreement, exhibit to this Agreement or schedule to this
Agreement, as the case may be, and references in any section or
definition to any clause means such clause of such section or
definition;
E. "Herein," "hereunder," "hereof," "hereto," and words of similar
import shall be deemed references to this Agreement as a whole
and not to any particular section or other provision of this
Agreement;
F. "Including" (and with the correlative meaning "include") means
including without limiting the generality of any description
preceding such term;
G. Relative to the determination of any period of time, "from" means
"from and including," "to" means "to but excluding" and "through"
means "through and including";
H. Reference to any law (including statutes and ordinances) means
such law as amended, modified, codified or reenacted, in whole or
in part, and in effect from time to time, including rules and
regulations promulgated thereunder;
I. All accounting terms not specifically defined herein shall be
construed in accordance with GAAP in effect on the date hereof -
"GAAP" shall mean generally accepted accounting principles set
forth in the opinions and pronouncements of the Accounting
Principles Board of the American Institute of Certified Public
Accountants and statement and pronouncements of the Financial
Accounting Standards Board, applied on a consistent basis.
J. In the event of any conflict between any of the provisions of the
body of this Agreement and any exhibit or schedule hereto, the
provisions of the body of this Agreement shall control;
K. The headings contained in this Agreement have been inserted for
convenience of reference only, and are not to be used in
construing this Agreement; and
L. Any rule of construction or interpretation which might otherwise
require this Agreement to be construed or interpreted against
either party shall not apply to any construction or
interpretation hereof.
16. Notices. All notices, requests, demands, and other communications
permitted or required under this Agreement shall be in writing and
shall be either personally
9
delivered (including couriers such as Federal Express) or sent by pre-
paid certified mail, return receipt requested, or facsimile
transmission, with a confirmation copy personally delivered or sent by
pre-paid certified mail, addressed or transmitted to the address set
forth above of the party or the facsimile number stated below of the
party to which notice is given, or to such other address or facsimile
number as such party may have fixed by notice given in accordance with
the terms hereof:
To any member of the Nexell Group, to:
President
Nexell Therapeutics Inc.
Facsimile Number: (000) 000-0000
President
Nexell of California, Inc.
Facsimile Number: (000) 000-0000
With a copy to:
Xxxxx Xxxx LLP
000 Xxxxxxxxxx Xxxxxx, X.X.
Xxxxxxxxxx, XX 00000-0000
Attn: Xxxx X. Xxxxx, Esq.
Facsimile Number: (000) 000-0000
To Baxter:
President - Venture Management
Facsimile Number: (000) 000-0000
Xxx X. Xxxxxxxx, Esq. - Assistant General Counsel
Facsimile Number: (000) 000-0000
With a copy to:
Seyfarth, Shaw, Xxxxxxxxxxx & Xxxxxxxxx
00 Xxxx Xxxxxx Xxxxxx
Xxxxxxx, Xxxxxxxx 00000-0000
Attn: Xxxxxxxxxxx X. Xxxxx, Esq.
Facsimile Number: (000) 000-0000
Any notice, sent as provided above, shall be deemed given if
personally delivered or, if sent by certified mail, upon delivery at
the address provided for above (or, in the
10
event delivery is refused, the first date on which delivery was
tendered) or, if sent by facsimile transmission, upon receipt by the
sender of confirmation of delivery.
[THE REMAINDER OF THIS PAGE IS INTENTIONALLY LEFT BLANK]
11
IN WITNESS WHEREOF, the parties have duly executed this Agreement as of the
date first set forth above.
XXXXXX HEALTHCARE CORPORATION
By:______________________________
Name:
Title:
NEXELL THERAPEUTICS INC
By:______________________________
Name:
Title:
NEXELL OF CALIFORNIA, INC
By:______________________________
Name:
Title:
12
Schedule 1.2(B)
For the purposes of Section 1.2(B) of the Royalty Agreement, the defined
term "Distributed Products" means, collectively, the finished goods of the
Isolex(R) and Maxsep(R) Products and Reagent Kits and other goods used in
conjunction with Isolex(R) and Maxsep(R) Products, as indicated in this Schedule
1.2(B).
For the purposes of this definition, Isolex(R) and Maxsep(R) Products
means, individually and collectively, the products listed on this Schedule
1.2(B), which includes Isolex(R) and Maxsep(R) instruments and Isolex(R) and
Maxsep(R) disposable sets, in each case as produced by Xxxxxx as of December 17,
1997, which utilize automated systems for positive and negative immunomagnetic
cell selection. From time to time, the products listed on this Schedule 1.2(B)
will be changed by the parties to add new products, line extensions and
improvements which were under development or were in research as of December 17,
1997, or have been identified as proposed new products in Schedule 1 of the
Manufacturing Agreement, or that Baxter agreed to develop pursuant to the
Original Services Agreement, in each case as consistent with the nature of the
Isolex(R) and Maxsep(R) Products existing as of December 17, 1997 and with
Xxxxxx'x legal obligations and technological capabilities (including, without
limitation, regulatory requirements applicable to Baxter) up to the US Asset
Transfer Closing Date (as defined in the Asset Transfer Agreement), and such new
products, line extensions and improvements added to this Schedule 1.2(B) shall
thereafter be treated as Isolex(R) and Maxsep(R) Products for all purposes of
this Agreement.
For the purposes of this definition, Reagent Kits means the reagent kits
specified in Schedule 1 to the Antibody Agreement and such other reagent kits as
may be used from time to time in connection with the Isolex(R) and Maxsep(R)
Products.11234
1
Distributed Products as of June 30, 1999
-------------------------------------------------------------------------------
SELECTION REAGENTS
Breast Cancer Tumor Removal
-------------------------------------------------------------------------------
RAR9941 MaxSep Breast Tumor 55KD MAb, Research Ex-Vivo Use
-------------------------------------------------------------------------------
RAR9938 MaxSep Breast Tumor 200KD MAb, Research Ex-Vivo Use
-------------------------------------------------------------------------------
RAR9948 MaxSep Breast Tumor 42KD MAb, Research Ex-Vivo Use
-------------------------------------------------------------------------------
ITX1041 Anti-Breast Cancer MAb Inv. Kit
-------------------------------------------------------------------------------
-------------------------------------------------------------------------------
SELECTION REAGENTS
B-Cell Removal
Anti-CD19 Antibodies
-------------------------------------------------------------------------------
FAR9929 Anti-Human CD19-Research Use Only
-------------------------------------------------------------------------------
RAR9909 Anti-Human CD19, CE Xxxx
-------------------------------------------------------------------------------
FAR9590 CTI-Anti-Human CD19, Immunoselection MAbs
-------------------------------------------------------------------------------
-------------------------------------------------------------------------------
Anti-CD20 Antibodies
-------------------------------------------------------------------------------
RAR9920 Anti-Human CD20 (CE Xxxx)
-------------------------------------------------------------------------------
-------------------------------------------------------------------------------
Isolex B-Cell Positive/Negative/With CD19/CD20
-------------------------------------------------------------------------------
ITX1035 Isolex 300 Reagent Kit +/- B-Cell Kit
-------------------------------------------------------------------------------
-------------------------------------------------------------------------------
Anti-CD10 Antibodies
-------------------------------------------------------------------------------
RAR9901 Anti Human CD10
-------------------------------------------------------------------------------
ITX1031 Anti-Human CD10, Investigational, Eng. Lang.
-------------------------------------------------------------------------------
ITX1032 Anti-Human CD10, Investigational, Ger. Lang.
-------------------------------------------------------------------------------
-------------------------------------------------------------------------------
Anti-CD22 Antibodies
-------------------------------------------------------------------------------
FAR9927 Anti-Human CD22 - Research Use Only
-------------------------------------------------------------------------------
RAR9926 Anti-Human CD22- CE Xxxx
-------------------------------------------------------------------------------
-------------------------------------------------------------------------------
Anti-CD23 Antibodies
-------------------------------------------------------------------------------
RAR9931 Anti-Human CD23
-------------------------------------------------------------------------------
-------------------------------------------------------------------------------
Anti-CD37 Antibodies
-------------------------------------------------------------------------------
RAR9934 Anti-Human CD37
-------------------------------------------------------------------------------
-------------------------------------------------------------------------------
SELECTION REAGENTS
T-Cell Selection
-------------------------------------------------------------------------------
FAR9908 MAb, CD8, Research Use
-------------------------------------------------------------------------------
FAR9904 MAb, CD4, Research Use
-------------------------------------------------------------------------------
ITX1038 MAb, CD8, Clinical, German Labeled
-------------------------------------------------------------------------------
ITX1037 MAb, CD4, Clinical, German Labeled
-------------------------------------------------------------------------------
ITX1021 MAb, CD4, Research
-------------------------------------------------------------------------------
2
-------------------------------------------------------------------------------
ITX1022 MAb, CD8, Research
-------------------------------------------------------------------------------
-------------------------------------------------------------------------------
SELECTION REAGENTS
Process Solutions
EDR9865Phosphate Buffered Saline, 3 LT
-------------------------------------------------------------------------------
-------------------------------------------------------------------------------
SELECTION REAGENTS
NON-GMP DYNAL PRODUCTS
(U.S. only)
-------------------------------------------------------------------------------
4R5425 Dynabeads (M-450 Sheep antiMouse IgG) 10 mL
-------------------------------------------------------------------------------
4R9947 DETACHabead 4/8 5mL
-------------------------------------------------------------------------------
4R9949 Dynabeads M-450 CD14 10 mL
-------------------------------------------------------------------------------
4R5439 Dynabeads (M-450 CD4) IgM 10 mL
-------------------------------------------------------------------------------
4R4513 MPC-1 Magnetic Particle Concentrator
-------------------------------------------------------------------------------
4R5429 Dynabeads (M-450 goat antiMouse IgG) 10 mL
-------------------------------------------------------------------------------
4R5421 Dynabeads (M-450 Uncoated) 10 mL
-------------------------------------------------------------------------------
4R5441 Dynabeads (M-450 CD8) 10 mL
-------------------------------------------------------------------------------
4R5435 Dynabeads (M-450 Pan-T CD2) 10 mL
-------------------------------------------------------------------------------
4R5453 Dynabeads M-450 Sheep anti Mouse IgG1 (fc)ST, 10 mL
-------------------------------------------------------------------------------
4R5427 Dynabeads M-450 Sheep anti Mouse IgG1 (fc), 10 ml
-------------------------------------------------------------------------------
4R5431 Xxxxxxxxx X-000 Sheep anti-Rat IgG(Fc) 10 ml
-------------------------------------------------------------------------------
4R5437 Xxxxxxxxx X-000 Pan-B, 10 ml
-------------------------------------------------------------------------------
4R5423 Xxxxxxxxx X-000 Tosyl activated, 10 ml
-------------------------------------------------------------------------------
4R5443 Dynabeads M-280 Streptavidin, 10ml
-------------------------------------------------------------------------------
4R5445 Dynabeads M-280 Sheep anti Mouse IgG 10 ml
-------------------------------------------------------------------------------
4R5447 Xxxxxxxxx X-000 Sheep anti-Rabbit IgG 10 ml
-------------------------------------------------------------------------------
4R5449 Xxxxxxxxx X-000 Tosyl-Activated, 10 ml
-------------------------------------------------------------------------------
4R5410 DETACHabead
-------------------------------------------------------------------------------
4R9947 DETACHabead 4/8
-------------------------------------------------------------------------------
4R5413 Dynabeads M-450 CD4
-------------------------------------------------------------------------------
-------------------------------------------------------------------------------
NON-SELECTION DISPOSABLES
Storage
-------------------------------------------------------------------------------
4R9952 Cryocyte 250 ml
-------------------------------------------------------------------------------
4R9951 Cryocyte 50 ml with label pocket
-------------------------------------------------------------------------------
4R9953 Cryocyte 250 ml with label pocket
-------------------------------------------------------------------------------
4R9959 Cryocyte 1000 ml with label pocket
-------------------------------------------------------------------------------
4R9954 Cryocyte 500 ml
-------------------------------------------------------------------------------
4R9956 Cryocyte 750 ml
-------------------------------------------------------------------------------
4R9958 Cryocyte 1000 ml
-------------------------------------------------------------------------------
4R9955 Cryocyte 500 ml with label pocket
-------------------------------------------------------------------------------
4R9957 Cryocyte 750 ml with label pocket
-------------------------------------------------------------------------------
4R5460 Cryocyte Manifold Set
-------------------------------------------------------------------------------
-------------------------------------------------------------------------------
NON-SELECTION DISPOSABLES
3
-------------------------------------------------------------------------------
Expansion/Modification
PL732-Lifecell, Solution Transfer, Harvester, Cell Wash
-------------------------------------------------------------------------------
4C2475 Lifecell Filter Adapter Set
-------------------------------------------------------------------------------
4C2476 Lifecell Adapter Set
-------------------------------------------------------------------------------
4C2474 Lifecell Transfer Set (obsolete >4R9605)
-------------------------------------------------------------------------------
4R9834 Centrifuge Adapter
-------------------------------------------------------------------------------
4R9833 Cell Wash Set
-------------------------------------------------------------------------------
4R2113 Lifecell PL732 Tissue Culture
-------------------------------------------------------------------------------
4R2110 Lifecell PL732 Tissue Culture
-------------------------------------------------------------------------------
3L2100 33 mm Cap and Septum Combination
-------------------------------------------------------------------------------
4R2113P Lifecell PL732 Tissue Culture
-------------------------------------------------------------------------------
4R2111 Lifecell PL732 Tissue Culture
-------------------------------------------------------------------------------
4C2470 Lifecell Transfer Set w/Integral Airway Connector
-------------------------------------------------------------------------------
5C4446 5 Prong Manifold Set
-------------------------------------------------------------------------------
5C4447 10 Prong Manifold Set
-------------------------------------------------------------------------------
HARVESTER SYSTEM
-------------------------------------------------------------------------------
4R2997 Harvester Disposable Set
-------------------------------------------------------------------------------
4R2999 Reservoir Set, used w/Harvester
-------------------------------------------------------------------------------
-------------------------------------------------------------------------------
NON-SELECTION DISPOSABLES
EXPANSION/MODIFICATION
PL2417 - Lifecell, Expansion
-------------------------------------------------------------------------------
ITX1009 PL2417 Tissue Culture Flask (100-500 mL)
-------------------------------------------------------------------------------
ITX1008 PL2417 Tissue Culture Flask (500-2000 mL)
-------------------------------------------------------------------------------
-------------------------------------------------------------------------------
NON-SELECTION HARDWARE
Harvester System
-------------------------------------------------------------------------------
4R4960 Fenwal Cell Harvester System
-------------------------------------------------------------------------------
4R4961 Cell Harvester System - International
-------------------------------------------------------------------------------
4R9832 Harvester Workstation
-------------------------------------------------------------------------------
4R4960R Fenwal Cell Harvester System (Refurbished)
-------------------------------------------------------------------------------
-------------------------------------------------------------------------------
NON-SELECTION HARDWARE
Solution Transfer Pump
-------------------------------------------------------------------------------
4R4345 Solution Transfer Pump
-------------------------------------------------------------------------------
-------------------------------------------------------------------------------
DISTRIBUTED ASSAY KITS
-------------------------------------------------------------------------------
4R9900 Stem Cell CFU Kit for Research Use 35 tests
-------------------------------------------------------------------------------
FAR9864 Epimet Epithelial Cell Detection Fixation Sol. B
-------------------------------------------------------------------------------
FAR9863 Epimet Epithelial Cell Detection Kit
-------------------------------------------------------------------------------
FAR9871 Epimet Epithelial Cell Detection Sample Kit
-------------------------------------------------------------------------------
-------------------------------------------------------------------------------
SELECTION HARDWARE
MaxSep
-------------------------------------------------------------------------------
4R4511 MaxSep Magnetic Cell Separator
-------------------------------------------------------------------------------
4R4511R MaxSep Magnetic Cell Separator (refurbished)
-------------------------------------------------------------------------------
R4R9709 MaxSep Magnetic Cell Separator
-------------------------------------------------------------------------------
-------------------------------------------------------------------------------
SELECTION HARDWARE
Isolex 50
-------------------------------------------------------------------------------
4
-------------------------------------------------------------------------------
4R4519 Isolex 50 Magnetic Cell Separator
-------------------------------------------------------------------------------
4R4516 Rotator-Adapter for Isolex 50
-------------------------------------------------------------------------------
-------------------------------------------------------------------------------
SELECTION HARDWARE
Isolex 300SA
-------------------------------------------------------------------------------
ITX1048 Isolex(TM) 300SA, Research Labeled
-------------------------------------------------------------------------------
OFTX1027 Isolex(TM) 300SA, Investigational
-------------------------------------------------------------------------------
OR4R9722 Isolex(TM) 300SA (CE-Marked)
-------------------------------------------------------------------------------
OITX1006 Isolex 300 Adapter for 50mL Chamber
-------------------------------------------------------------------------------
-------------------------------------------------------------------------------
SELECTION HARDWARE
Isolex 300i
-------------------------------------------------------------------------------
ITX1051 Isolex 300i Instrument, Research Labeling
-------------------------------------------------------------------------------
ITX1017 Isolex 300i Instrument
-------------------------------------------------------------------------------
R4R9750 Isolex 300(i) (CE-Marked)
SELECTION DISPOSABLES
MaxSep
-------------------------------------------------------------------------------
4R5401 MaxSep Disposable Set
-------------------------------------------------------------------------------
ITX1011 MaxSep Disposables (Clinical)
-------------------------------------------------------------------------------
R4R9700 MaxSep Disposable Set CE Xxxx
-------------------------------------------------------------------------------
-------------------------------------------------------------------------------
-------------------------------------------------------------------------------
SELECTION DISPOSABLES
Isolex 50
-------------------------------------------------------------------------------
4R5402 Disposable Set for Isolex 50
-------------------------------------------------------------------------------
-------------------------------------------------------------------------------
SELECTION DISPOSABLES
Isolex 300SA
-------------------------------------------------------------------------------
ITX1050 Isolex(TM) 300 Disposable Set, Research Labeling
-------------------------------------------------------------------------------
OFTX1028 Isolex(TM) 300 Disposable Set
-------------------------------------------------------------------------------
OR4R9720 Isolex(TM) 300 Disposable Set (XX-Xxxx)
-------------------------------------------------------------------------------
-------------------------------------------------------------------------------
SELECTION DISPOSABLES
Isolex 300i
-------------------------------------------------------------------------------
ITX1052 Isolex 300i Disposable Set, Research Labeling
-------------------------------------------------------------------------------
ITX1016 Isolex 300i Disposable Set
-------------------------------------------------------------------------------
R4R9751 Isolex 300 (i) Disposable Set (CE-Marked)
-------------------------------------------------------------------------------
SELECTION REAGENTS
CD34 Positive Selection
-------------------------------------------------------------------------------
4R9540 Isolex 50 Stem Cell Res. Kit w/Peptide
-------------------------------------------------------------------------------
ITX1049 Isolex 300 SA/I Reagent Kit, Research
-------------------------------------------------------------------------------
ITX1030 Isolex 300 Reagent Kit (1-1-1) w/SC Releasing Agnt
-------------------------------------------------------------------------------
R4R9752 Isolex 300 Stem Cell Reagent Kit (CE-Marked)
-------------------------------------------------------------------------------
5
-------------------------------------------------------------------------------
-------------------------------------------------------------------------------
SELECTION REAGENTS
Beads for Magnetic Selection
-------------------------------------------------------------------------------
4R9950 Dynabeads XXX IgG 10ml GMP, Research Label
-------------------------------------------------------------------------------
ITX1053 Dynabeads XXX IgG 10ml GMP, Invest. Labeling
-------------------------------------------------------------------------------
RAR9950 Dynabeads XXX IgG 10ml GMP (CE Marked)
-------------------------------------------------------------------------------
-------------------------------------------------------------------------------
SELECTION REAGENTS
Bulk Purified Sheep-Anti Mouse Contract Manufacture for Dynal
-------------------------------------------------------------------------------
RAR9905 Sheep, Anti-Mouse MAB to Dynal
-------------------------------------------------------------------------------
6
